Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Mar 5, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.166, Talquetamab-tgvs (Talvey™)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Mar 5, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.166 for Talquetamab-tgvs (Talvey™) has been reissued and updated. This affects coverage and billing requirements for this specialty oncology medication used to treat multiple myeloma.

Action Required

Action needed

By March 5, 2025: Billing team should review the updated MA08.166 policy for Talquetamab-tgvs (Talvey™) at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing guidelines for Medicare Advantage plans. Update billing procedures and staff training accordingly based on the full policy details.

Related policy hubs

Independence Blue Cross policies Oncology Hematology